Clinical trial
A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT07441980 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- March 2, 2026
- Completion date
- June 30, 2028
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed/refractory acute myeloid leukemia(aml)